FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4298088082> ?p ?o ?g. }

• W4298088082 endingPage "2903" @default.
• W4298088082 startingPage "2892" @default.
• W4298088082 abstract "Nearly a century after its first description, configurationally stable axial chirality remains a rare feature in marketed drugs. In the development of the KRASG12C inhibitor sotorasib (LUMAKRAS/LUMYKRAS), an axially chiral biaryl moiety proved a critical structural element in engaging a cryptic protein binding pocket and enhancing inhibitor potency. Restricted rotation about this axis of chirality gave rise to configurationally stable atropisomers that demonstrated a 10-fold difference in potency. The decision to develop sotorasib as a single-atropisomer drug gave rise to a range of analytical and synthetic challenges, whose resolution we review here.Assessing the configurational stability of differentially substituted biaryl units in early inhibitor candidates represented the first challenge to be overcome, as differing atropisomer stability profiles called for differing development strategies (e.g., as rapidly equilibrating rotamers vs as single atropisomers). We relied on a range of NMR, HPLC, and computational methods to assess atropisomer stability. Here, we describe the various variable-temperature NMR, time-course NMR, and chiral HPLC approaches used to assess the configurational stability of axially chiral bonds displaying a range of rotational barriers.As optimal engagement of the cryptic pocket of KRASG12C was ultimately achieved with a configurationally stable atropisomeric linkage, the second challenge to be overcome entailed preparing the preferred (M)-atropisomer of sotorasib on industrial scale. This synthetic challenge centered on the large-scale synthesis of an atropisomerically pure building block comprising the central azaquinazolinone and pyridine rings of sotorasib. We examined a range of strategies to prepare this compound as a single atropisomer: asymmetric catalysis, chiral chromatographic purification, and classical resolution. Although chiral liquid and simulated moving bed chromatography provided expedient access to initial multikilo supplies of this key intermediate, a classical resolution process was ultimately developed that proved significantly more efficient on metric-ton scale. To avoid discarding half of the material from this resolution, this process was subsequently refined to enable thermal recycling of the undesired atropisomer, providing an even more efficient commercial process that proved both robust and green.While the preparation of sotorasib as a single atropisomer significantly increased both the analytical and synthetic complexity of its development, the axially chiral biaryl linkage that gave rise to the atropisomerism of sotorasib proved a key design element in optimizing sotorasib's binding to KRASG12C. It is hoped that this review will help in outlining the range of analytical techniques and synthetic strategies that can be brought to bear in addressing the challenges posed by such axially chiral compounds and that this account may provide helpful guidelines for future efforts aimed at the development of such single atropisomer, axially chiral pharmaceutical agents." @default.
• W4298088082 created "2022-10-01" @default.
• W4298088082 creator A5010634877 @default.
• W4298088082 creator A5033094493 @default.
• W4298088082 creator A5066345448 @default.
• W4298088082 date "2022-09-30" @default.
• W4298088082 modified "2023-10-05" @default.
• W4298088082 title "Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations" @default.
• W4298088082 cites W1997077098 @default.
• W4298088082 cites W2026783351 @default.
• W4298088082 cites W2042910018 @default.
• W4298088082 cites W2052245082 @default.
• W4298088082 cites W2053678935 @default.
• W4298088082 cites W2058616449 @default.
• W4298088082 cites W2087313629 @default.
• W4298088082 cites W2122839730 @default.
• W4298088082 cites W2137739964 @default.
• W4298088082 cites W2141218040 @default.
• W4298088082 cites W2142340513 @default.
• W4298088082 cites W2322474371 @default.
• W4298088082 cites W2335442430 @default.
• W4298088082 cites W2340115217 @default.
• W4298088082 cites W2474436045 @default.
• W4298088082 cites W2588957810 @default.
• W4298088082 cites W2771897018 @default.
• W4298088082 cites W2786849322 @default.
• W4298088082 cites W2804171113 @default.
• W4298088082 cites W2891809493 @default.
• W4298088082 cites W2905520504 @default.
• W4298088082 cites W2952624002 @default.
• W4298088082 cites W2969336671 @default.
• W4298088082 cites W2994953911 @default.
• W4298088082 cites W3008811731 @default.
• W4298088082 cites W3092961736 @default.
• W4298088082 cites W3101949422 @default.
• W4298088082 cites W3143666723 @default.
• W4298088082 cites W3196216303 @default.
• W4298088082 cites W3206323135 @default.
• W4298088082 cites W4213385974 @default.
• W4298088082 cites W4231423004 @default.
• W4298088082 cites W4248891552 @default.
• W4298088082 cites W4283169451 @default.
• W4298088082 cites W4292808920 @default.
• W4298088082 cites W4292809578 @default.
• W4298088082 doi "https://doi.org/10.1021/acs.accounts.2c00479" @default.
• W4298088082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36178208" @default.
• W4298088082 hasPublicationYear "2022" @default.
• W4298088082 type Work @default.
• W4298088082 citedByCount "10" @default.
• W4298088082 countsByYear W42980880822022 @default.
• W4298088082 countsByYear W42980880822023 @default.
• W4298088082 crossrefType "journal-article" @default.
• W4298088082 hasAuthorship W4298088082A5010634877 @default.
• W4298088082 hasAuthorship W4298088082A5033094493 @default.
• W4298088082 hasAuthorship W4298088082A5066345448 @default.
• W4298088082 hasBestOaLocation W42980880821 @default.
• W4298088082 hasConcept C121332964 @default.
• W4298088082 hasConcept C124668440 @default.
• W4298088082 hasConcept C146686406 @default.
• W4298088082 hasConcept C161790260 @default.
• W4298088082 hasConcept C167981757 @default.
• W4298088082 hasConcept C178790620 @default.
• W4298088082 hasConcept C185592680 @default.
• W4298088082 hasConcept C18705241 @default.
• W4298088082 hasConcept C201977512 @default.
• W4298088082 hasConcept C20621625 @default.
• W4298088082 hasConcept C21951064 @default.
• W4298088082 hasConcept C2776568683 @default.
• W4298088082 hasConcept C32909587 @default.
• W4298088082 hasConcept C52703039 @default.
• W4298088082 hasConcept C62520636 @default.
• W4298088082 hasConcept C71240020 @default.
• W4298088082 hasConcept C7602139 @default.
• W4298088082 hasConceptScore W4298088082C121332964 @default.
• W4298088082 hasConceptScore W4298088082C124668440 @default.
• W4298088082 hasConceptScore W4298088082C146686406 @default.
• W4298088082 hasConceptScore W4298088082C161790260 @default.
• W4298088082 hasConceptScore W4298088082C167981757 @default.
• W4298088082 hasConceptScore W4298088082C178790620 @default.
• W4298088082 hasConceptScore W4298088082C185592680 @default.
• W4298088082 hasConceptScore W4298088082C18705241 @default.
• W4298088082 hasConceptScore W4298088082C201977512 @default.
• W4298088082 hasConceptScore W4298088082C20621625 @default.
• W4298088082 hasConceptScore W4298088082C21951064 @default.
• W4298088082 hasConceptScore W4298088082C2776568683 @default.
• W4298088082 hasConceptScore W4298088082C32909587 @default.
• W4298088082 hasConceptScore W4298088082C52703039 @default.
• W4298088082 hasConceptScore W4298088082C62520636 @default.
• W4298088082 hasConceptScore W4298088082C71240020 @default.
• W4298088082 hasConceptScore W4298088082C7602139 @default.
• W4298088082 hasFunder F4320307105 @default.
• W4298088082 hasIssue "20" @default.
• W4298088082 hasLocation W42980880821 @default.
• W4298088082 hasLocation W42980880822 @default.
• W4298088082 hasLocation W42980880823 @default.
• W4298088082 hasOpenAccess W4298088082 @default.
• W4298088082 hasPrimaryLocation W42980880821 @default.
• W4298088082 hasRelatedWork W2033371833 @default.

• next